Search
Lantheus Holdings Inc
LNTHAdd to Watchlist
109.010USD
+4.160+3.97%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
7.09BMarket Cap
25.78P/E TTM
More Details of Lantheus Holdings Inc Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Lantheus Holdings Inc Info
Ticker SymbolLNTH
Company nameLantheus Holdings Inc
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Number of employees808
Security typeOrdinary Share
Fiscal year-endJun 25
Address331 Treble Cove Road
CityNORTH BILLERICA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01862
Phone19786718001
Websitehttps://www.lantheus.com/
Ticker SymbolLNTH
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Company Executives of Lantheus Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
4.70K
+88.02%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
FAQs
Who are the top five shareholders of Lantheus Holdings Inc?
The top five shareholders of Lantheus Holdings Inc are: Ms. Mary Anne Heino
How many institutions hold shares of Lantheus Holdings Inc (LNTH)?
As of 2026Q1, 1043 institutions hold shares of Lantheus Holdings Inc, with a combined market value of approximately 77.80M, accounting for 119.49% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5936003.00.
